1. 5 chemical reasons given for KERX obtaining an extension for its key patent.
2. Besides, it has 2 other patents (until 2024 and 2026) which a generic would have to "invent around."
3. Regardless, Europe (30% of Zenerex' market) will almost certainly give KERX 10 year exclusivity.
4. The extremely strong anemia data may INCREASE Zenerex IP protection and protect it for DECADES.
Sentiment: Strong Buy
shorts already did most of the damage, the stock is about to stabilize..at this point I think most investors who are holding or buying KERX do know that shorts are wrong here and IP is not an issue